多西他赛联合卡培他滨治疗耐药性晚期乳腺癌疗效观察

目的观察及评价周剂量多西他赛联合卡培他滨治疗蒽环类药物耐药晚期乳腺癌的疗效和不良反应。方法46例经病理证实的蒽环类耐药性晚期乳腺癌患者，采用多西他赛联合卡培他滨方案化疗，多西他赛35mg／m^2、静脉滴注、d1、d8，卡培他滨1250mg／（m^2·d），分2次口服、d1～d14，21d为1个周期，化疗周期数为2～8个周期，中位周期数4个，直至病情进展或不良反应无法耐受。结果46例患者中，完全缓解6例（13．0％），部分缓解23例（50．0％），稳定13例（28．9％），疾病进展4例（8．7％），有效率为63．0％。不良反应主要为胃肠道反应、骨髓抑制和手足综合征，患者均可耐受。结论周剂量多西他赛联合卡培他滨治疗蒽环类耐药性晚期乳腺癌的疗效确切及毒副反应轻，患者耐受性好，值得临床推广。

Effect of docetaxel combined with capecitabine on anthracycline resistant advanced breast cancer

Aim To evaluate the efficacy and toxicity of weekly docetaxel in combination with capecitabine con anthraeyeline-resistant advanced breast carcinoma. Methods Forty-six patients with antllracycline-resistant advanced breast carcinoma were treated with doeetaxel combined with capeeitabine .Docetaxel was administered intravenously at a dose of 35 mg/m^2 on D1D8.and oral intake of capecitabine at a dose of 1250mg/（m^2·d） from dl to dl4,every 21 days as a cycle. The median number of cycles was 4 （2-8 cycles）. Results The overall remission rate was 63.0% ,and a complete remmision rate of 13.0% and partial remission rate of 50.0% .The most common toxicities were gastrointestinal reaction and hematological toxicity. All of them were reversible. Conclusion Docetaxel combined with capecitabine is an effective and well tolerated alternative in treatment of antllracycline-resistant advanced breast carcinoma..